## **DEPARTMENT OF HEALTH & HUMAN SERVICES**

Public Health Service Food and Drug Administration

8050 99 JUN -1 A10:01 Memorandum

Date:

MAY 27 1999

From:

Brian J. Malkin, Associate Director for Patents and Hearings

Health Assessment Policy Staff (HFY-20)

Subject: Patent Term Restoration Application


for GlucaGen®

To:

Dockets Management (HFA-305)

Attached is a letter to the Patent Term Office for the above mentioned human drug product under the Docket Number 98E-0853 stating that this particular patent is eligible for regulatory review. The Patent Number is 4,826,763. Please place this recent correspondence in the appropriate file.

If you have any questions, please contact me at 827-6620. Thank you for your assistance.



MAY 27 1999

Re: GlucaGen® Docket No. 98E-0853

The Honorable Q. Todd Dickinson
Deputy Assistant Commissioner for Patent Policy and Projects
U.S. Patent and Trademark Office
Box Pat. Ext.
Assistant Commissioner for Patents
Washington, D.C. 20231

Dear Commissioner Dickinson:

This is in regard to the application for patent term extension for U.S. Patent No. 4,826,763 filed by Novo Nordisk A/S under 35 U.S.C. § 156. The human drug product claimed by the patent is GlucaGen® (glucagon (rDNA origin)), which was assigned new drug application (NDA) No. 20-918.

A review of the Food and Drug Administration's official records indicates that this product was subject to a regulatory review period before its commercial marketing or use, as required under 35 U.S.C. § 156(a)(4). Our records also indicate that it represents the first permitted commercial marketing or use of the product, as defined under 35 U.S.C. § 156(f)(1), and interpreted by the courts in <u>Glaxo Operations UK Ltd. v. Quigg</u>, 706 F. Supp. 1224 (E.D. Va. 1989), <u>aff'd</u>, 894 F. 2d 392 (Fed. Cir. 1990). The product is the first permitted commercial marketing of the product produced using recombinant DNA technology.

The NDA was approved on June 22, 1998, which makes the submission of the patent term extension application on August 20, 1998, timely within the meaning of 35 U.S.C. § 156(d)(1).

Should you conclude that the subject patent is eligible for patent term extension, please advise us accordingly. As required by 35 U.S.C. § 156(d)(2)(A) we will then determine the applicable regulatory review period, publish the determination in the Federal Register, and notify you of our determination.

Please let me know if we can be of further assistance.

Sincerely yours,

Rónald L. Wilson, Director Health Assessment Policy Staff

Office of Health Affairs

CC:

Carol E. Rozek c/o Novo Nordisk of North America, Inc. Suite 6400 405 Lexington Avenue New York, NY 10174-6401